Provided by Tiger Trade Technology Pte. Ltd.

VanEck Biotech ETF

242.35
-1.3764-0.56%
Volume:2K
Turnover:374.05K
Market Cap:479.01M
PE:- -
High:242.41
Open:242.41
Low:242.26
Close:243.73
52wk High:244.35
52wk Low:160.91
Shares:1.98M
Float Shares:1.98M
Volume Ratio:0.49
T/O Rate:0.08%
Dividend:0.95
Dividend Rate:0.39%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Sanofi, Regeneron Seem Keen to Keep Working Together

Dow Jones
·
Aug 07

Alphabet Reports Share Stake in SpaceX, Fervo Energy and Parabilis Medicines

Reuters
·
Aug 07

Alphabet Inc. Cuts Share Stake in Revolution Medicines Inc by 10.5% to 2.9 Mln Shares - SEC Filing

THOMSON REUTERS
·
Aug 07

Sino Biopharmaceutical Stock Climbs 3.3% in Hong Kong, Outperforms Competitors

Dow Jones
·
Aug 07

Moderna Inc. Stock Sheds 4.3%, Underperforms Peers

Dow Jones
·
Aug 07

Regeneron Posts Transcript of Q2 2026 Earnings Conference Call

Reuters
·
Aug 07

Vortex Energy Study Confirms Major Salt Structure and New Target at Robinsons River

TIPRANKS
·
Aug 07

Regeneron Canada Says Libtayo Receives Health Canada Approval for Treatment of a Type of Carcinoma

Reuters
·
Aug 06

Regeneron announces Health Canada approval of new indication for Libtayo

TIPRANKS
·
Aug 06

Regeneron Canada: Libtayo Receives Health Canada Approval for Adjuvant Treatment of High-Risk Cutaneous Squamous Cell Carcinoma

THOMSON REUTERS
·
Aug 06

Bernstein Remains a Hold on Revolution Medicines (RVMD)

TIPRANKS
·
Aug 06

Salesforce, UnitedHealth Share Losses Contribute to Dow's Nearly 150-Point Drop

Dow Jones
·
Aug 06

Analysts Have Conflicting Sentiments on These Healthcare Companies: Revolution Medicines (RVMD), Royalty Pharma (RPRX) and Urogen Pharma (URGN)

TIPRANKS
·
Aug 06

Intellia Therapeutics Q2 Collaboration Revenue Falls, Net Loss Widens

Reuters
·
Aug 06

Intellia Q2 FY26 Net Loss Widens to $106.63 Million; Revenue Falls to $7.66 Million

Reuters
·
Aug 06

Generate Biomedicines Q2 FY26 Net Loss Widens to $67.26 Million; Revenue Drops to $6.31 Million

Reuters
·
Aug 06

Revolution Medicines, Inc. : Needham Raises Target Price to $240 from $236

THOMSON REUTERS
·
Aug 06

Revolution Medicines Publishes Corporate Deck Outlining Ras(on) Inhibitor Pipeline Targeting RAS-Driven Cancers

Reuters
·
Aug 06

Revolution Medicines, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 06

Exelixis Q2 Revenue Misses Analyst Estimates, Lowers 2026 Outlook

Reuters
·
Aug 06